Novartis’ canakinumab cuts risk for heart attack survivors
Novartis to discuss canakinumab results with regulators.
X
Novartis’ canakinumab cuts risk for heart attack survivors
https://pharmaphorum.com/news/novartis-canakinumab-reduces/
Novartis to discuss canakinumab results with regulators.